Haleon Pakistan Limited · PSX:HALEON
Haleon Pakistan — Investor Presentation (2024)
17 slides from Haleon Pakistan's investor presentation, Nov 25, 2024
Slide 1: Corporate Briefing Session 2024
Corporate Briefing Session 2024
Slide 2: Quran Recitation
Quran Recitation
Slide 3: Our Story, Business Overview, Key Financials
Our Story Business Overview Key Financials Question and Answers
Slide 4: Our Story
Our Story In pursuant of the demerger of the consumer healthcare business from GlaxoSmithKline plc, UK on July 18, 2022, to Haleon plc. an independent listed Company (listed on London Stock Exchange and New York Stock Exchange), the ultimate parent Company has changed from GlaxoSmithKline plc to Hal
Slide 5: Corporate Information
Corporate Information Board of Directors Management Committee Mr. Farhan Muhammad Chief Executive Officer Haroon Mr. M. Z. Moin Mohajir (Chairperson) Mr. Dilawar Meghani Mr. Dilawar Meghani Chief Financial Officer Mr. Farhan Muhammad Haroon Ms. Sumru Atalay Besceli Legal Director and Company Syed An
Slide 6: Business Overview
Our Story Business Overview Key Financials Question and Answers
Slide 7: Expanding portfolio through organic and inorganic growth model
Expanding portfolio through organic and inorganic growth model GSK Consumer Healthcare Novartis Pfizer Brands become part of Haleon as a result of Brands become part of Haleon as a result of Brands become part of Haleon as a result of demerger of consumer healthcare business from demerger of consume
Slide 8: Brands Portfolio
Brands Portfolio FMCG OVER THE COUNTER Oral Care Nutrition & Skin Health Respiratory Pain Relief Digestive
Slide 9: Recent Key Launches
Pain Recent Key Launches Panadol Night Panadol Ultra OH Sensodyne Kids Senso Access 9
Slide 10: Revenue & EPS growth
Revenue & EPS growth 31,610 Revenue – Rs Million 27,507 27,513 24,163 19,846 14,875 16,317 8,298 2017 2018 2019 2020 2021 2022 2023 9M 2024 27.4 Earning per share - Rs 18.2 10.8 10.8 9.2 8.5 7.4 2.8 2017 2018 2019 2020 2021 2022 2023 9M 2024
Slide 11: Portfolio wise Sales – YTD September
PKR in million Portfolio wise Sales – YTD September Maintaining the upward trend by doing what matter most! Net Sales OTC Portfolio Net Sales FMCG +18% vs last year +7% vs last year Total Company Net Sales +16% vs last year 19,720 23,214 3,062 3,284 2023 2024 2023 2024 Tolling – NVS Exports +10% vs
Slide 12: Key Brands Performance
Key Brands Performance Top 3 Brands contribute 80% to Total turnover
Slide 13: Responsible Business
Responsible Business Responsible Business Inaugration of Solar power Sustainability Generation Project Composting site in Jamshoro Haleon X TCF HALEON x UNICEF Community “Mothers Matter” Supporting a school in Matiari, Sindh Welfare Corporate Dar Ul Sukoon “Haleon Helps” Volunteering 13
Slide 14: Awards and Achievements
Awards and Achievements The Pakistan Pharmaceutical Manufacturing Guinness Book of World Records for “Largest Association (PPMA) declared Haleon amongst Attendance for a pharmaceutical conference in one TOP 10 Pharmaceutical exporters of Pakistan. day” Haleon Limited secured 2nd Position for Best Co
Slide 15: Key Financials
Our Story Business Overview Key Financials Question and Answers
Slide 16: Key Financial Highlights
Key Financial Highlights Nine months ended 2024 results PKR 27.5Bn PKR 9.2Bn PKR 5.4Bn Revenue Gross Profit Profit before tax Revenue: Growth of 16% vs SPLY – Higher by PKR 3.8bn. PKR 27.4 PKR 11.4 Gross Profit: Earning per share Q3 Earning per share Gross margin at 33.3%, +14.5% (PKR 4.7bn) vs SPLY
Slide 17: Q&A